Ratings by Raymond James (Laura Prendergast)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/15/2025 | Mural Oncology | MURA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2025 | Third Harmonic Bio | thrd | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/26/2025 | Erasca Inc | ERAS | New Coverage | Outperform (N/A) |
1.48 (15.03) |
915.54% | Details | |
| 3/25/2025 | Mural Oncology | MURA | Downgrade | Outperform (Strong Buy) |
3.83 (2.04) |
-46.74% | Details | |
| 2/11/2025 | Third Harmonic Bio | THRD | Downgrade | Market Perform (Outperform) |
4.65 (5.38) |
15.7% | Details | |
| 10/4/2024 | Mural Oncology | MURA | New Coverage | Strong Buy (N/A) |
3.20 (3.83) |
19.69% | Details | |
| 8/14/2024 | Nkarta Inc. | NKTX | Upgrade | Strong Buy (Outperform) |
5.07 (3.10) |
-38.86% | Details | |
| 7/31/2024 | Black Diamond Therapeutics | BDTX | New Coverage | Outperform (N/A) |
6.02 (2.48) |
-58.8% | Details | |
| 6/7/2024 | Third Harmonic Bio | THRD | New Coverage | Outperform (N/A) |
13.74 (4.65) |
-66.16% | Details | |
| 4/10/2024 | Revolution | RVMD | Upgrade | Strong Buy (Outperform) |
31.91 (46.24) |
44.91% | Details | |
| 3/22/2024 | Nkarta Inc. | NKTX | Downgrade | Outperform (Strong Buy) |
12.79 (5.07) |
-60.36% | Details |
